skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Saracatinib (Code C48378)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Saracatinib

Definition: An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.

NCI-GLOSS Definition: A substance being studied in the treatment of some types of cancer. AZD0530 blocks enzymes needed for cancer growth. It is a type of tyrosine kinase inhibitor.

Display Name: Saracatinib

Label: Saracatinib

NCI Thesaurus Code: C48378 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2828242  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-
SRC Kinase Inhibitor AZD0530

External Source Codes: 
CAS Registry Number 379231-04-6 (see NLM ChemIDplus info)
NSC Code 735464 (see NCI DTP info)
PDQ Closed Trial Search ID 453588
PDQ Open Trial Search ID 453588 (check for NCI PDQ open clinical trial info)
UMLS CUI C2828242

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C27H32ClN5O5
code C48378
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name AZD0530
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom